reason report
biosim impact harder upsid multipl
bottom line earn beat continu rate abbvi
share market perform given wors anticip ex-u humira
total sale biosimilar eros varieti headwind
growth profit reduc revenu
forecast start earn forecast
reduc price target given
chang decreas peer multipl slow growth
morn report small revenu beat
ep beat versu consensu increas non
gaap ep guidanc reflect strong ep beat
driven better expect margin perform
seem unlik continu manag commentari
guidanc expect biosimilar eros ex-u humira
revenu notic cautiou pace eros seem like
almost doubl rate previous suggest manag
versu two-year period
previous reinforc increas uncertainti
face compani previous known metronom predict
investor like question much faster pace eros
occur one-third busi still negoti
compani suggest pace eros moder
like fall deaf ear also cast doubt reliabl
manag famou guidanc predict humira
sale total sale
believ biosimilar surpris increas investor
skeptic reliabl growth outlook particularli
disappoint stemcentrx portfolio face
erod price power us market compani tax rate
like trend slightli higher next year rather drop fund
requir two major product launch year see
compani ep growth come courtesi share buyback
year presum next year well compani organ
growth like low mid singl digit next year compar
mid teen year compani recent multipl compress
neg estim revis may harbing thing come
sever quarter reduc price target
reiter market perform rate stock
previous cover highlight
confer call recap note link
compani inform leerink partner llc research
revenu mm dilut ep includ option expens present
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings p/sale
pleas refer page import disclosur price chart analyst certif
price target per share stock rate market perform
transit corpor ownership success larg independ
biopharmaceut compani mani best featur biotech pharma
resourc expertis infrastructur diversif larg pharma competitor
specialti product profil matur biotechnolog compani remain highli depend
singl franchis humira sale total sale suggest
us valuat still discount compar diversifi peer
multipl settlement us biosimilar entrant postpon eros brand domest
eros europ underway appear sharper faster prior
product abbvi abil control destini may fade depend action
new entrant even us would surpris see pressur humira
growth new entrant chang regul legal oversight manag care
pbm contract still expect oncolog product imbruvica venclexta becom
signific product gener revenu
compani hcv product maintain roughli pariti share competitor gilead
scienc look compani array promis late-stag clinic medicin
inflamm metabol diseas struggl expand oncolog franchis beyond
imbruvica venclexta current pipelin establish product contribut
singl digit revenu growth unlik off-set massiv headwind
face biosimilar enter market compet humira
imbruvica strength us humira inventori build support top-lin beat total
product revenu consensu miss estim
global humira sale sequenti
consensu line forecast us humira revenu
consensu forecast aid mid-singl digit price increas
channel inventori build-up product new formul meanwhil ex-u humira
revenu miss consensu estim last quarter
market exclus europ us imbruvica sale grew sequenti
impress consensu forecast
abbvi row profit share imbruvica grew sequenti line
consensu hcv revenu quarter viekira mavyret miss expect
multipl quarter beat primarili due declin ex-u patient wareh
effect experienc us hcv revenu increas sequenti
came consensu estim expect row hcv revenu
decreas sequenti came consensu estim
expect product sale mostli strong quarter
signific consensu beat kaletra androgel
lower expens share count contribut ep beat total non-gaap expens
less consensu estim driven lower
anticip expens categori quarter result oper margin
improv better consensu expect abbvi tax
rate in-lin expect guidanc share count
consensu expect result report non-gaap ep grew
annual consensu estim
full-year earn guidanc increas base oper result
quarter expect adjust ep rang increas
compar consensu updat estim abbvi
expect total revenu grow oper previous exclus
addit fx tailwind continu expect oper margin guidanc
approach compar consensu updat estim also
updat product level revenu guidanc us imbruvica reduc
guidanc ex-u humira compani provid full-year
guidanc mention expect double-digit ep growth
acknowledg encount challeng revenu growth year
line guidanc forecast humira row sale erod least yoy
first sever year manag guid humira sale row could see
eros expect eros slow given expect
eros rate blend europ biosimilar humira agent launch octob
part ou biosimilar humira may avail everi region
suggest estim eros rate eu higher think reason
estim larg line observ eros biolog
product europ remain skeptic whether eros slow follow
year base histor eros remicad enbrel two anti-tnf recent
biosimilar entri annual sale declin steepen subsequ year exampl
annual eros rate remicad first second third
roll period respect similarli enbrel annual eros rate
first second roll period respect faster eros remicad
appear relat size product may relat number
biosimilar entrant remicad enbrel larg compar sale eu prior
biosimilar competit remicad seen biosimilar launch first year
date enbrel seen time frame date consid greater
number biosimilar entrant humira launch pend approv
aggress price competit occur far believ eros eu least
high remicad higher like persist much rate sever year
least
scarc upcom catalyst list includ minor data present two import
drug approv compani late stage pipelin larg matur await regulatori
decis catalyst flow much slimmer prior month
compani report full data orilissa uterin fibroid year file label expans
multipl imbruvica venclexta trial frontlin chronic lymphocyt leukemia cll
also anticip present import regulatori approv occur
within next month venclexta slate acceler approv aml
risankizumab anticip approv psoriasi pdufa date april
model updat reduc us humira hcv estim pt follow result
guidanc updat revis revenu earn forecast better reflect
compani outlook decreas forecast humira
reflect faster ex-u price eros howev increas
revenu imbruvica venclexta later year due strong trend
forthcom label expans hematolog asset decreas revenu
forecast mavyret year captur expect manag
competitor number treat patient lessen go forward also made
signific neg chang kaletra duodopa total revenu forecast
decreas updat total revenu forecast
line recent consensu consensu
new forecast total revenu grow modestli recent
consensu well manag prior guidanc
forecast oper margin reduc percentag
point estim margin forecast still assum signific
growth decreas estim pro-forma dilut ep
forecast larg unchang reduc
recent consensu pro-forma dilut ep consensu
net result adjust chang sector valuat multipl bring
target price previous
price target base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar larg biopharmaceut compani price sale multipl
larg cap peer compani stock discount cash flow dcf appli peer ep
revenu multipl use averag larg cap larg molecul therapeut compani mid-
term growth tail risk celg sni rhhbi averag
consensu ep multipl appli current ep estim
give valu use revenu multipl similar compani
consensu sale appli revenu estim give
valu lastli dcf valuat given wacc termin cash flow growth rate
begin humira biosimilar entri give present valu averag
three method current price target
risk view outlook valuat includ major chang price
outlook reimburs coverag label competit posit humira compani
main product risk includ commerci develop disappoint compani
follow-on program inflammatori diseas imbruvica venclexta expand
hematolog malign well competit posit compani next-
gener hcv therapi assum oper margin stabil around
acceler revenu eros could neg affect margin outlook
compani remain highli lever commit grow dividend reduct
forecast ebitda due neg busi trend would place compani capit alloc
strategi dividend growth risk opportun upsid expect includ
stronger-than-expect price volum share humira emerg tangibl
demand underappreci element compani early-to-mid stage pipelin asset
potenti label expans opportun late stage opportun
non-gaap cost good sold
interest expens
abbvi guidanc
product ex venclexta specifi product
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
time event
allianc
leerink partner research compani report present clinicaltri gov
late stage pipelin program includ
late stage pipelin program exclud
bispecif mab i/o rova-t non-rova-t
million
leerink partner research compani file
million
good sold
 total revenu
sg total revenu
leerink partner research compani file
analysi stock price leerink target
method price base current larg cap hc stock mid-term growth tail risk
ep multipl appli ep rhhbi sni celg
leerink forma ep estim
method present valu base price sale multipl peer larg cap biopharma stock
averag price sale larg cap biopharma multipl
impli market cap mm estimate sale
anticip share count mm
method leerink probabl adjust dcf adjust net wacc termin
current leerink dcf marketed/l stage program
sourc leerink partner estim compani file factset
